RU2329823C2 - Стабилизированные твердые полипептидные частицы - Google Patents
Стабилизированные твердые полипептидные частицы Download PDFInfo
- Publication number
- RU2329823C2 RU2329823C2 RU2005116250/15A RU2005116250A RU2329823C2 RU 2329823 C2 RU2329823 C2 RU 2329823C2 RU 2005116250/15 A RU2005116250/15 A RU 2005116250/15A RU 2005116250 A RU2005116250 A RU 2005116250A RU 2329823 C2 RU2329823 C2 RU 2329823C2
- Authority
- RU
- Russia
- Prior art keywords
- polypeptide
- particles
- pacap
- solid
- stabilizing
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 239
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 221
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 216
- 239000002245 particle Substances 0.000 title claims abstract description 201
- 239000007787 solid Substances 0.000 title abstract description 129
- 230000003019 stabilising effect Effects 0.000 title 1
- 230000002378 acidificating effect Effects 0.000 claims abstract description 37
- 239000003381 stabilizer Substances 0.000 claims abstract description 11
- 102000030621 adenylate cyclase Human genes 0.000 claims abstract description 5
- 108060000200 adenylate cyclase Proteins 0.000 claims abstract description 5
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 3
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 3
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 claims description 166
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 claims description 127
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 claims description 127
- 239000000872 buffer Substances 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 26
- 239000007864 aqueous solution Substances 0.000 claims description 22
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 13
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 13
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 102000051325 Glucagon Human genes 0.000 claims description 11
- 108060003199 Glucagon Proteins 0.000 claims description 11
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 11
- 229960004666 glucagon Drugs 0.000 claims description 11
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- -1 methyl mannopyranoside Chemical compound 0.000 claims description 7
- 238000011084 recovery Methods 0.000 claims description 5
- 230000001817 pituitary effect Effects 0.000 claims description 4
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 claims description 3
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 3
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 108010086019 Secretin Proteins 0.000 claims description 2
- 102100037505 Secretin Human genes 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229960002101 secretin Drugs 0.000 claims description 2
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 1
- 102100022831 Somatoliberin Human genes 0.000 claims 1
- 101710142969 Somatoliberin Proteins 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000004153 glucose metabolism Effects 0.000 claims 1
- 125000000647 trehalose group Chemical group 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 abstract description 39
- 238000006731 degradation reaction Methods 0.000 abstract description 39
- 230000006641 stabilisation Effects 0.000 abstract description 20
- 238000003860 storage Methods 0.000 abstract description 10
- 230000004962 physiological condition Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 206010062767 Hypophysitis Diseases 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 description 124
- 239000000243 solution Substances 0.000 description 108
- 235000000346 sugar Nutrition 0.000 description 68
- 229930006000 Sucrose Natural products 0.000 description 40
- 239000005720 sucrose Substances 0.000 description 40
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 39
- 229910021645 metal ion Inorganic materials 0.000 description 38
- 239000000725 suspension Substances 0.000 description 35
- 230000015572 biosynthetic process Effects 0.000 description 31
- 238000000034 method Methods 0.000 description 29
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 19
- 238000011105 stabilization Methods 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 15
- 230000002776 aggregation Effects 0.000 description 14
- 238000004220 aggregation Methods 0.000 description 14
- 238000004108 freeze drying Methods 0.000 description 13
- 238000004007 reversed phase HPLC Methods 0.000 description 13
- 238000001542 size-exclusion chromatography Methods 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- 230000007935 neutral effect Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 150000008163 sugars Chemical class 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000012792 lyophilization process Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 6
- 238000001694 spray drying Methods 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000000368 destabilizing effect Effects 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000013618 particulate matter Substances 0.000 description 4
- 238000011287 therapeutic dose Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000005588 protonation Effects 0.000 description 3
- 239000012048 reactive intermediate Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 2
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013632 covalent dimer Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005935 nucleophilic addition reaction Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 229940074404 sodium succinate Drugs 0.000 description 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 101100459248 Mus musculus Mxra8 gene Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 description 1
- 101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42228902P | 2002-10-29 | 2002-10-29 | |
| US60/422,289 | 2002-10-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005116250A RU2005116250A (ru) | 2006-01-20 |
| RU2329823C2 true RU2329823C2 (ru) | 2008-07-27 |
Family
ID=32230336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005116250/15A RU2329823C2 (ru) | 2002-10-29 | 2003-10-28 | Стабилизированные твердые полипептидные частицы |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060198894A1 (es) |
| EP (1) | EP1562626B1 (es) |
| JP (1) | JP2006504772A (es) |
| KR (1) | KR20050083841A (es) |
| CN (1) | CN1708314A (es) |
| AU (1) | AU2003285075B2 (es) |
| BR (1) | BR0315782A (es) |
| CA (1) | CA2502378A1 (es) |
| DE (1) | DE60317822D1 (es) |
| EC (1) | ECSP055822A (es) |
| IL (1) | IL168106A0 (es) |
| MX (1) | MXPA05004593A (es) |
| MY (1) | MY138608A (es) |
| NO (1) | NO20052422L (es) |
| NZ (2) | NZ539811A (es) |
| PL (1) | PL376219A1 (es) |
| RU (1) | RU2329823C2 (es) |
| TW (1) | TW200505497A (es) |
| WO (1) | WO2004039392A2 (es) |
| ZA (1) | ZA200504311B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2264065B1 (en) | 2003-08-05 | 2017-03-08 | Novo Nordisk A/S | Novel insulin derivatives |
| US20190330295A1 (en) * | 2005-05-04 | 2019-10-31 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
| CN101389650B (zh) | 2005-12-28 | 2012-10-10 | 诺沃-诺迪斯克有限公司 | 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法 |
| JP4847775B2 (ja) * | 2006-03-29 | 2011-12-28 | シーシーアイ株式会社 | 安定なポリオール脱水素酵素組成物 |
| WO2008152106A1 (en) | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| ES2607003T3 (es) | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria |
| LT2603232T (lt) | 2010-08-11 | 2020-01-27 | Ironwood Pharmaceuticals, Inc. | Stabilios linaklotido vaisto formos |
| BR112013010345A2 (pt) | 2010-10-27 | 2017-07-25 | Novo Nordisk As | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção |
| EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| WO2024209050A1 (en) | 2023-04-05 | 2024-10-10 | Antag Therapeutics Aps | Gip activity modulators and orthostatic intolerance |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816440A (en) * | 1985-09-26 | 1989-03-28 | Cetus Corporation | Stable formulation of biologically active proteins for parenteral injection |
| US4806343A (en) * | 1986-03-13 | 1989-02-21 | University Of Southwestern Louisiana | Cryogenic protectant for proteins |
| JPH02218618A (ja) * | 1989-02-21 | 1990-08-31 | Green Cross Corp:The | トロンビン粉末製剤 |
| US5128242A (en) * | 1989-06-19 | 1992-07-07 | The Administrators Of The Tulane Educational Fund | Hypothalamic polypeptides with adenylate cyclase stimulating activity |
| ES2087323T3 (es) * | 1991-02-19 | 1996-07-16 | Takeda Chemical Industries Ltd | Metodo para producir peptidos exentos de cisteina. |
| JP3356816B2 (ja) * | 1992-03-24 | 2002-12-16 | セイコーインスツルメンツ株式会社 | 半導体光電気変換装置 |
| JPH083056A (ja) * | 1994-06-17 | 1996-01-09 | Nippon Kayaku Co Ltd | 末梢神経障害の軽減剤 |
| JPH08131171A (ja) * | 1994-11-11 | 1996-05-28 | Asahi Chem Ind Co Ltd | 逆転写酵素の安定化組成物 |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| PT877599E (pt) * | 1996-02-02 | 2003-08-29 | Alza Corp | Administracao continua de leuprolido utilizando um sistema implantavel |
| US6156331A (en) * | 1996-02-02 | 2000-12-05 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| US6395292B2 (en) * | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| PT949905E (pt) * | 1996-12-20 | 2001-12-28 | Alza Corp | Composicao de gel injectavel de efeito retardado e processo para a sua preparacao |
| BR9809304B1 (pt) * | 1997-04-28 | 2011-02-08 | formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária. | |
| JP4156688B2 (ja) * | 1997-07-22 | 2008-09-24 | アルフレッサファーマ株式会社 | 安定なヘモグロビン含有組成物 |
| JP4215188B2 (ja) * | 1997-12-22 | 2009-01-28 | インターシア セラピューティクス，インコーポレイティド | 薬剤供給を調節するデバイスのための速度調節膜 |
| EP1041974B1 (en) * | 1997-12-30 | 2006-10-11 | Alza Corporation | Beneficial agent delivery system with membrane plug |
| CN100448482C (zh) * | 1999-05-31 | 2009-01-07 | 三菱化学株式会社 | Hgf冻干制剂 |
| WO2003068805A2 (en) * | 2002-02-14 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Formulation strategies in stabilizing peptides in organic solvents and in dried states |
| GB0207092D0 (en) * | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
-
2003
- 2003-10-28 RU RU2005116250/15A patent/RU2329823C2/ru not_active IP Right Cessation
- 2003-10-28 EP EP03779390A patent/EP1562626B1/en not_active Expired - Lifetime
- 2003-10-28 MX MXPA05004593A patent/MXPA05004593A/es active IP Right Grant
- 2003-10-28 CA CA002502378A patent/CA2502378A1/en not_active Abandoned
- 2003-10-28 JP JP2004548544A patent/JP2006504772A/ja active Pending
- 2003-10-28 AU AU2003285075A patent/AU2003285075B2/en not_active Ceased
- 2003-10-28 CN CNA2003801023848A patent/CN1708314A/zh active Pending
- 2003-10-28 KR KR1020057007327A patent/KR20050083841A/ko not_active Application Discontinuation
- 2003-10-28 PL PL03376219A patent/PL376219A1/xx not_active Application Discontinuation
- 2003-10-28 BR BR0315782-2A patent/BR0315782A/pt not_active IP Right Cessation
- 2003-10-28 DE DE60317822T patent/DE60317822D1/de not_active Expired - Lifetime
- 2003-10-28 US US10/696,405 patent/US20060198894A1/en not_active Abandoned
- 2003-10-28 WO PCT/US2003/034229 patent/WO2004039392A2/en active IP Right Grant
- 2003-10-28 NZ NZ539811A patent/NZ539811A/en unknown
- 2003-10-28 NZ NZ562480A patent/NZ562480A/en not_active IP Right Cessation
- 2003-10-29 TW TW092129977A patent/TW200505497A/zh unknown
- 2003-10-29 MY MYPI20034115A patent/MY138608A/en unknown
-
2005
- 2005-04-18 IL IL168106A patent/IL168106A0/en unknown
- 2005-05-19 NO NO20052422A patent/NO20052422L/no not_active Application Discontinuation
- 2005-05-26 ZA ZA200504311A patent/ZA200504311B/en unknown
- 2005-05-30 EC EC2005005822A patent/ECSP055822A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05004593A (es) | 2005-07-26 |
| BR0315782A (pt) | 2005-09-20 |
| IL168106A0 (en) | 2009-02-11 |
| CA2502378A1 (en) | 2004-05-13 |
| WO2004039392A3 (en) | 2004-09-30 |
| JP2006504772A (ja) | 2006-02-09 |
| CN1708314A (zh) | 2005-12-14 |
| ECSP055822A (es) | 2005-08-11 |
| MY138608A (en) | 2009-07-31 |
| ZA200504311B (en) | 2006-07-26 |
| US20060198894A1 (en) | 2006-09-07 |
| PL376219A1 (en) | 2005-12-27 |
| AU2003285075A1 (en) | 2004-05-25 |
| RU2005116250A (ru) | 2006-01-20 |
| WO2004039392A2 (en) | 2004-05-13 |
| EP1562626B1 (en) | 2007-11-28 |
| NZ562480A (en) | 2009-08-28 |
| AU2003285075B2 (en) | 2009-10-29 |
| TW200505497A (en) | 2005-02-16 |
| EP1562626A2 (en) | 2005-08-17 |
| DE60317822D1 (de) | 2008-01-10 |
| NO20052422L (no) | 2005-07-20 |
| NO20052422D0 (no) | 2005-05-19 |
| KR20050083841A (ko) | 2005-08-26 |
| NZ539811A (en) | 2008-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2586459B1 (en) | Vegf antagonist formulations | |
| ZA200504311B (en) | Stabilized, solid-state polypeptide particles | |
| US6174856B1 (en) | Stabilized insulin compositions | |
| CA2602249C (en) | Peptide and protein formulations with improved stability | |
| KR101978527B1 (ko) | 펩티드 약물의 비경구 주입을 위한 안정한 제형 | |
| EP3452079B1 (en) | Insulin formulations comprising polysorbate 80 | |
| Chang et al. | Development of a stable freeze-dried formulation of recombinant human interleukin-1 receptor antagonist | |
| JP2017531665A (ja) | ペプチド又はタンパク質薬物を経口送達するための医薬製剤 | |
| CZ433898A3 (cs) | Nevodné protické peptidové formulace | |
| US20050009739A1 (en) | Formulation strategies in stabilizing peptides in organic solvents and in dried states | |
| TW201832783A (zh) | 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物 | |
| US10702611B2 (en) | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates | |
| CZ298464B6 (cs) | Vodné formulace peptidu | |
| CN101715340A (zh) | 促胰岛素释放肽的混悬制剂及其应用 | |
| KR20230121822A (ko) | Glp-1/glp-2 이중 효능제의 약학적 조성물 | |
| EP3225235B1 (en) | Stable peptide formulations for parenteral injection | |
| CN101980699A (zh) | 液体和冻干制剂 | |
| KR20190090061A (ko) | 당뇨병 치료를 위한 제형물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20081029 |